Schizophrenia/Psychosis

From overutilization of emergency departments to reversible clomiphene-associated manic episodes, here are highlights from the week in Psychiatric Times.

What can we learn from sleep in schizophrenia? New research sheds light.

Although ulotaront was well-tolerated, results for patients treated with it were not superior to those for patients treated with placebo.

The experts weighed in on a wide variety of psychiatric issues for the July 2023 issue of Psychiatric Times.

“She would never hurt her baby...”

How does schizophrenia differ between men and women, and what does this mean for developing treatment strategies?

Did you miss our APA Annual Meeting coverage?

This mother shares her experience of having a loved one with schizophrenia, and the difference location can make in treatment.

The experts weighed in on a wide variety of psychiatric issues for the June 2023 issue of Psychiatric Times.

Check out the evidence for a modest effect over 1 year of clozapine dose on weight.

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

Researchers used an observational cohort study to investigate a potential causal association.

Researchers investigated relationships between sleep problems, suicidal ideation, and psychopathology in patients with first-episode psychosis.

The experts weighed in on a wide variety of psychiatric issues for the May 2023 issue of Psychiatric Times.

An inside look at what treatments are being discussed in San Francisco...

Data presents opportunities to enhance care and improve treatment adherence.

Research explores the differences between new-onset psychosis in patients with infection versus healthy controls.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

Individuals with schizophrenia have experienced an increase in psychiatric, medical, and treatment risks because of the COVID-19 pandemic.

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.

The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.

The experts weighed in on a wide variety of psychiatric issues for the April 2023 issue of Psychiatric Times.

From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.

What does cancer treatment mean for psychiatric treatment with clozapine?

What are the key diagnostic differences between schizophrenia and schizoaffective disorder?

Schizophrenia is one of the most recognized yet least understood chronic brain disorders.

What are some of the most important contemporary issues in schizophrenia and the ways research can inform exemplary clinical practice?